

Resource Summary Report

Generated by [dkNET](#) on Aug 23, 2026

TZM-bl

RRID:CVCL_B478

Type: Cell Line

Proper Citation

BEI_Resources Cat# ARP-8129, RRID:CVCL_B478

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B478

Proper Citation: BEI_Resources Cat# ARP-8129, RRID:CVCL_B478

Description: Cell line TZM-bl is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-related endocervical adenocarcinoma

Defining Citation: [PMID:18842727](#), [PMID:19474095](#)

Comments: Population: African American.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TZM-bl

Synonyms: TZM, JC53-bl, JC53BL-13, JC.53bl-13, JC53-bl clone 13

Cross References: BTO:BTO_0005059, BEI_Resources:ARP-8129, ChEMBL-Cells:ChEMBL3307662, ChEMBL-Targets:ChEMBL614612, PubChem_Cell_line:CVCL_B478, Wikidata:Q54973492

ID: CVCL_B478

Vendor: BEI_Resources

Catalog Number: ARP-8129

Hierarchy: cvcl_0030

Record Creation Time: 20250130T072906+0000

Record Last Update: 20260816T001452+0000

Ratings and Alerts

No rating or validation information has been found for TZM-bl.

No alerts have been found for TZM-bl.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 157 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

von Maltitz P, et al. (2026) Identification and Characterization of an In Silico Designed Membrane-Active Peptide with Antiviral Properties. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e13911.

Tsuji K, et al. (2026) CD4 Mimic-Neutralizing Antibody Conjugates Synthesized by Site-Specific Modification Methods as HIV-1 Entry Inhibitors. ChemMedChem, 21(3), e202500820.

Rantalainen K, et al. (2026) Virus glycoprotein nanodisc platform for vaccine analytics. Nature communications, 17(1).

Giron LB, et al. (2026) Inhibiting glycan degradation prevents HIV-induced inflammaging and cognitive impairment. Med (New York, N.Y.), 7(7), 101175.

Ranaweera A, et al. (2026) Capsid and integrase play essential apposing roles in viral ribonucleoprotein assembly during HIV-1 core morphogenesis. iScience, 29(7), 116378.

Kaginkar S, et al. (2026) Immune and viral surveillance of HIV-1C reservoirs in an Indian cohort. iScience, 29(1), 114278.

Hammoudi A, et al. (2026) Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses. EBioMedicine, 127, 106269.

Immel JR, et al. (2026) A Priori Design, Combinatorial Synthesis, and Assessment of an Antipackaging Peptide Against Human Immunodeficiency Virus 1: Functional Role of Unnatural Trp Mimetics and Serendipitous Discovery of a Protease Inhibitor. ChemMedChem, 21(13), e70372.

Müller TG, et al. (2026) Lenacapavir-induced capsid damage uncovers HIV-1 genomes emanating from nuclear speckles. The EMBO journal, 45(2), 449.

Grigorieva EV, et al. (2026) Transmission of Non-Constitutive Proteasomes Between Cells via Extracellular Vesicles. *International journal of molecular sciences*, 27(1).

Galvez NMS, et al. (2026) HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice. *Immunity*, 59(3), 768.

Kratochvil S, et al. (2026) Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity. *iScience*, 29(6), 116022.

Jansen J, et al. (2026) Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency. *PloS one*, 21(7), e0348959.

Gramatica A, et al. (2025) EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8⁺ T cells toward less-exhausted phenotypes. *Cell reports*, 44(5), 115652.

Hahn PA, et al. (2025) Exogenous estrogen enhances T cell activation in male primates. *Cell reports*, 44(9), 116170.

Xie Z, et al. (2025) Simultaneous priming of HIV broadly neutralizing antibody precursors to multiple epitopes by germline-targeting mRNA-LNP immunogens in mouse models. *Science immunology*, 10(112), eadu7961.

Xue J, et al. (2025) An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques. *Cell reports*, 44(9), 116228.

Tsuji K, et al. (2025) Hybrid Molecules of Small Molecular and Peptidic HIV Fusion Inhibitors. *Chembiochem : a European journal of chemical biology*, 26(13), e202500230.

Abdalla AL, et al. (2025) Lithium attenuates HIV-1 latency reversal in an autophagy-independent way. *iScience*, 28(12), 114085.

Hesselman MC, et al. (2025) Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development. *Cell host & microbe*, 33(2), 279.